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DNA damage activates TP53-regulated surveillance mechanisms that are crucial in 
suppressing tumorigenesis. TP53 orchestrates these responses directly by 
transcriptionally modulating genes, including microRNAs (miRNAs), and by regulating 
miRNA biogenesis through interacting with the DROSHA complex. However, whether 
the association between miRNAs and AGO2 is regulated following DNA damage is not 
yet known. Here we show that, following DNA damage, TP53 interacts with AGO2 to 
induce or reduce AGO2’s association of a subset of miRNAs, including multiple let-7 
family members. Furthermore, we show that specific mutations in TP53 decrease rather 
than increase the association of let-7 family miRNAs, reducing their activity without 
preventing TP53 from interacting with AGO2. This is consistent with the oncogenic 
properties of these mutants. Using AGO2 RIP-seq and PAR-CLIP-seq we show that the 
DNA-damage-induced increase in binding of let-7 family members to the RISC complex 
is functional. We unambiguously determine the global miRNA-mRNA interaction 
networks involved in the DNA damage response, validating them through the 
identification of miRNA-target chimeras formed by endogenous ligation reactions. We 
find that the target complementary region of the let-7 seed tends to have highly fixed 
positions and more variable ones. Additionally, we observe that miRNAs whose cellular 
abundance or differential association with AGO2 is regulated by TP53 are involved in 
an intricate network of regulatory feedback and feedforward circuits. TP53-mediated 
regulation of AGO2-miRNA interaction represents a new mechanism of miRNA 
regulation in carcinogenesis.  
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Introduction 
DNA damage activates TP53, which acting principally as a transcription factor, directs DNA 
repair or, where irreparable damage has occurred, the initiation of programmed cell death. It 
does so by orchestrating the transcription of a number of messenger RNAs (mRNAs) 
(Menendez et al. 2009), non-coding RNAs [both long non-coding RNAs (lncRNAs) (Hung et 
al. 2011) and microRNAs (miRNAs)] which are involved in controlling these pathways (Krell 
et al. 2013). TP53 also modulates the nuclear biogenesis step of a group of miRNAs by 
interacting with the DROSHA complex, through the DEAD box RNA helicase DDX5 
(Suzuki et al. 2009). A number of chemotherapeutic agents with anti-cancer activity act as 
DNA damaging agents, including doxorubicin (DOX), which induces double-strand DNA 
breaks (DSBs) that activate TP53-mediated cell signalling pathways such as apoptosis, 
senescence and cell cycle arrest (Krell et al. 2013; Kruiswijk et al. 2015). DOX is widely used 
to activate DNA damage in cell lines in order to study TP53 function.  
Mutations in, or inactivation of, TP53 are the most frequent abnormalities observed in cancer 
cells (Hollstein et al. 1991). Furthermore, miRNAs are often dys-regulated in cancer 
indicating that refining our knowledge of their roles in TP53-signalling networks and their 
gene targets is crucial to achieving a greater understanding of tumorigenesis.  
Importantly, miRNAs only become active regulators of their mRNA targets once they interact 
with AGO1-4 proteins, the key components of the RNA-induced silencing complexes 
(RISCs). When loaded with a miRNA, AGO proteins inhibit the expression of their targets, 
recognising them through miRNA-target base pairing (Bartel 2009).  
Isolation and sequencing of RNAs (RNA-seq) that interact with AGO proteins has been 
widely performed to globally identify functional miRNA targets in vivo, at single nucleotide 
resolution. These include Photoactivatable-Ribonucleoside-Enhanced Crosslinking and 
Immunoprecipitation followed by deep sequencing (PAR-CLIP-seq), High-Throughput 
Sequencing of RNA isolated by Crosslinking Immunoprecipitation (HITS-CLIP), individual-
Nucleotide resolution Cross-Linking and Immunoprecipitation (iCLIP) and, finally, RNA 
Immunoprecipitation followed by deep sequencing (RIP-seq) (Chi et al. 2009; Hafner et al. 
 Cold Spring Harbor Laboratory Press on January 31, 2016 - Published by genome.cshlp.orgDownloaded from 
TP53 regulates miRNA-AGO2 association 
 
 
4 
 
2010; Konig et al. 2011; Schraivogel et al. 2011). More recently these techniques have been 
coupled with Crosslinking, Ligation, and Sequencing of Hybrids (CLASH), a technique 
involving a ligation reaction during the RNA preparation step to covalently join miRNAs to 
the RNA regions with which they interact (Helwak et al. 2013; Helwak and Tollervey 2014). 
Following this procedure, the bioinformatic isolation and analysis of the chimeric products 
allows the unambiguous identification of miRNA targets (Helwak et al. 2013; Grosswendt et 
al. 2014; Helwak and Tollervey 2014). 
Importantly, despite the regulation of miRNA biogenesis has been extensively explored, both 
at the transcription and maturation levels, to the best of our knowledge, modulation of the 
association between miRNAs and the RISC complex upon cellular stimulation has not been 
previously demonstrated. In light of this, we hypothesized that modulation of miRNA 
association with AGO2 could be a further step in the regulation of miRNA activity upon 
specific cellular stimuli. Thus, we aimed to investigate whether such a mechanism might 
represent a novel TP53-mediated process, capable of regulating miRNA activity in a different 
manner to those previously described, and with relevance to the DNA-damage response and 
carcinogenesis.  
 
 Results 
TP53 regulates the association between a subgroup of miRNAs and AGO2 
To evaluate if DNA damage induced by DSBs affects the association between certain 
miRNAs and the RISC complex, we stimulated either TP53+/+ or TP53-/- HCT116 human 
colon cancer cell lines with DOX for 24 hours (h) and performed small RNA-seq from total 
RNA and from RNA purified from immunoprecipitated AGO2 (AGO2-RIP-seq), analysed 
using a tailored bioinformatics pipeline (Supplemental Fig. S1 and supplemental methods). 
As illustrated in Supplemental Figure S2A, a number of miRNAs exhibited a statistically 
significant, TP53-dependent increase or decrease in cellular abundance (Benjamini-Hochberg 
adjusted Student's t-test P-value < 0.05) following DOX treatment. Here, we confirmed the 
TP53-dependent up-regulation of miR-34a, miR-143 and miR-107, consistent with previous 
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findings (He et al. 2007; Suzuki et al. 2009) supporting the reliability of our approach 
(Supplemental Fig. S2A and Supplemental Table S1). However, a number of miRNAs 
demonstrated an increase or decrease in cellular abundance in both TP53+/+ and TP53-/- cells 
following DOX treatment (Supplemental Fig. S2B and Supplemental Table S1), indicating 
that these expression changes occurred in a TP53-independent manner. Interestingly, our 
small RNA-seq approach identified, for the first time, that miR-3065-3p and miR-3065-5p are 
the miRNAs most strongly up-regulated by DNA damage (Supplemental Fig. S2B and 
Supplemental Table S1). This occurred in a TP53-independent manner (Supplemental Fig. 
S2B and Supplemental Table S1) indicating that these miRNAs could be central to the DNA 
damage response, and we validated this finding by RT-qPCR (Supplemental Fig. S2C).  
 
Strikingly, whilst for many miRNAs their increase in abundance on AGO2 correlated with an 
increase in cellular expression (Fig. 1A marked ‘&’ and Fig. 1B), for a subset, DNA-damage 
modulated their association with AGO2 (Benjamini-Hochberg adjusted Student's t-test P-
value < 0.05) but not their cellular abundance (Fig. 1A marked ‘o’; Fig. C and Supplemental 
Fig. S3A). This occurred in a TP53-dependent manner (Fig. 1A and C) as no change in 
miRNA association with AGO2 was seen in HCT116 TP53-/- cells (Fig 1D). Interestingly, at 
least three members of the let-7 family exhibited such increases in AGO2 binding (Fig. 1A, C 
and Supplemental Fig. S3A) that were not due to changes in AGO2 expression (Supplemental 
Fig. S3B). To increase our confidence in defining the miRNAs whose abundance was 
regulated by DNA damage, we only considered those whose expression was changed in a 
comparable manner in both the AGO2-RIP-seq and the RNA-seq experiments (Fig. 1A, 
marked ‘&’; and Fig. 1B). Briefly, we identified 10 miRNAs that were up-regulated and 2 
that were down-regulated in a TP53-dependent manner (Fig. 1A marked ‘&’; and Fig.1B), 
and 6 miRNAs that were up-regulated and 3 that were down-regulated independently of TP53 
(Fig. 1D marked ‘&’). Furthermore, we identified 26 miRNAs whose association with AGO2 
increased and 15 whose association with AGO2 decreased following DOX treatment, without 
their expression levels changing, finding that this only occurred in the presence of wild type 
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TP53 (Fig. 1A marked ‘o’; Fig. 1C and Supplemental Table S1).  
 
The association of AGO2 with let-7 family miRNAs is significantly increased in response 
to DOX in the presence of wild type TP53 but is decreased in the presence of mutant 
TP53  
The role of let-7 miRNAs in repressing cell cycle and cancer progression has been 
demonstrated by several independent groups (Boyerinas et al. 2010). However, their 
abundance has not been found to change in response to DSBs stimulated by DOX treatment 
in HCT116 cells in this (Fig. 1B, 1C, Supplemental Fig. 2A and Supplemental Table 1) or 
previous high-throughput studies (Chang et al. 2007; He et al. 2007; Suzuki et al. 2009). 
Strikingly, our results indicate a novel mechanism whereby, instead of modulating the cellular 
abundance of the let-7 family, DSBs increase the association between these miRNAs and 
AGO2. Having identified a TP53-dependent modulation of AGO2 binding for 3 members of 
the let-7 family, and considering their roles in negatively regulating cell cycle progression, we 
subsequently examined expression levels of all let-7 family members in our small RNA-seq 
and RIP-seq data. Specifically, we compared the changes in the expression levels induced by 
DNA damage (i.e. log fold changes of DOX-treated vs untreated samples) between total RNA 
and AGO-Immunoprecipitated RNA data for both TP53+/+ and TP53-/- cells. This revealed a 
significant TP53-dependent regulatory effect on the association between AGO2 and the entire 
let-7 family apart from let-7d (Fig. 2A) and we validated these findings by RT-qPCR (Fig. 
2B, C). The cellular abundance of both let-7f and let-7g was unchanged during a time course 
experiment following 1 to 24h of DOX treatment (Fig. 2D), indicating that the TP53-
dependent increase in their association with AGO2 demonstrated after 24h treatment, was not 
due to an earlier and transient increase in let-7 expression within the treatment period. We 
also confirmed a decreased association between miR-148a-5p and AGO2 in response to DOX 
treatment (Fig. 2E) while no significant change in miR-148a-5p expression was observed in a 
time course experiment (Supplemental Fig. S3C). Strikingly, the association between let-7c or 
let-7i and AGO2 significantly increased in both HCT116 TP53+/+ (Fig. 2A, B) and wild type 
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RKO human colon cancer cell lines (Fig. 2F) but did not change in DLD1 human colon 
cancer cell lines that expressed a mutated form of TP53 (Fig. 2F). Re-introduction of wild 
type TP53 into HCT116 TP53-/- cells restored both the induction of miR-34a and the 
increased association between let-7 and AGO2 in response to DOX (Fig. 2G). Noticeably, the 
introduction of two mutant TP53 proteins (R175H and R248W) into HCT116 TP53-/- cells, 
which have been shown to exert oncogenic instead of tumor suppressive activity (Liu et al. 
2010), significantly reduced the association between let-7 and AGO2 (Fig. 2G), while a third 
TP53 mutant (R273H) lost its capacity to affect this association.  
 
TP53 interacts with AGO2 in both the cytoplasmic and nuclear compartments following 
DOX-mediated DSBs 
Co-IP experiments indicated that wild type and mutant TP53 variants all interact with AGO2 
after DOX treatment (Fig. 3A, B). Interestingly, the interaction between AGO2 and TP53 was 
decreased after RNase treatment, alongside increases in the unbound supernatant (Fig. 3C), 
indicating that RNAs enhance the AGO2-TP53 association. The interaction between TP53 
and AGO2 was previously demonstrated in a genome wide association study in Drosophila 
melanogaster (Lunardi et al. 2010), demonstrating that this co-binding is highly conserved 
across species. Next, we used a Proximity Ligation Assay (PLA) in untreated and DOX-
treated cells to evaluate the cellular compartment in which this binding occurs, following 
DNA damage (Fig. 4A). We found that TP53 interacted with AGO2 after 24h of DOX 
treatment (Fig. 4A), consistent with our demonstration of a TP53-dependent mechanism 
regulating the association between AGO2 and a subgroup of miRNAs (Fig. 1A, C). 
Interestingly, AGO2-TP53 complexes were present in both the cytoplasm and the nucleus 
following 24h of DOX treatment (Fig. 4A, C), but the majority were located in the nucleus 
(Fig. 4A, C), indicating that additional functions may be exerted by this complex in the 
nuclear compartment. Accordingly, it has been previously demonstrated that DICER1- and 
DROSHA-dependent functional small RNAs arise from DSBs (Francia et al. 2012). This, 
coupled with our results, suggests that AGO2 may interact with this small RNA population in 
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the nucleus. AGO2 was actively imported into the nucleus upon DOX treatment, 
independently of TP53 (Supplemental Fig. S4A, B). The absence of fluorescent spots, over 
the background level, in HCT116 TP53-/- cells indicated the existence of a specific interaction 
(Fig. 4B). AGO2-TP53 binding occurred in response to DOX in both wild type (Fig. 3A and 
Fig. 4A, C) and TP53 mutant expressing cells (Fig. 3B), but the TP53-dependent effect on the 
let-7’s association with AGO2 was different in cells with mutant TP53 (Fig. 2G).  
 
A set of transcripts whose cellular abundance does not change following the induction of 
DSBs, are differentially associated with AGO2.  
Next, we wished to determine the mRNA targets of the DNA damage-regulated miRNAs. It is 
known that TP53 directly activates the transcription of several genes (Wei et al. 2006) in 
response to DNA damage. However, very little is known about the fraction of genes that do 
not change at the transcriptional level but that are post-transcriptionally regulated in response 
to DNA damage. To identify genes that may be post-transcriptionally regulated through an 
AGO2-miRNA interaction, but are not transcriptionally modulated, we performed RNA-seq 
and AGO2-RIP-seq of poly-adenylated transcripts (Supplemental Table S2 and Supplemental 
Fig. S5). As expected, our RNA-seq showed extensive deregulation of genes involved in 
apoptosis, DNA damage response and cell cycle (Supplemental Fig. S6A-F and Supplemental 
Table S3) as well as previously described TP53 targets (Supplemental Fig. S6A). Consistent 
with our previous findings (Krell et al. 2014), expression of snoRNAs derived from the GAS5 
locus was also increased via TP53 (Supplemental Table S2). Notably, by combining our 
RNA-seq and AGO2-RIP-seq data we identified 144 and 161 genes whose binding onto 
AGO2 increased and decreased respectively in response to DNA damage in both replicates, 
but whose expression showed no change in total RNA samples (Supplemental Fig. S6G), 
indicating that these genes are post-transcriptionally regulated through a DNA damage 
mediated miRNA-AGO2-target interaction. A pathway enrichment analysis involving these 
two groups of genes did not show any significant category of gene enrichment when the P-
values were adjusted for multiple hypothesis testing. Nevertheless, we noticed that among the 
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transcripts that were more associated with AGO2 (indicative of increased repression by 
miRNAs) following DNA damage, at least 8 code for proteins that negatively regulate 
apoptosis (Supplemental Fig. S7A). Conversely among the transcripts less associated with 
AGO2 (possibly because their repression by miRNAs was released) in response to DSBs 
there were at least 9 that code for proteins involved in DNA repair (Supplemental Fig. S7B) 
demonstrating that this regulation might be important for the DNA damage response. 
In addition, among the transcripts that were either more or less associated with AGO2 
following DOX treatment, 31 are annotated as lncRNAs and 12 as pseudogenes 
(Supplemental Table S2) suggesting that competing activity between miRNAs and non-
coding RNAs (Poliseno et al. 2010; de Giorgio et al. 2013) might occur during the DNA 
damage response. NEAT1 was among the lncRNAs whose association with AGO2 was 
reduced by DNA damage (Supplemental Table S2). This lncRNA is essential for the 
formation of paraspeckles (Clemson et al. 2009) which have been implicated in cancer cell 
survival (Choudhry et al. 2015). 
Importantly, transcripts that were more associated with AGO2 in response to DNA damage 
were significantly enriched for let-7 seed matches (Supplemental Table S4), indicating that 
the above-mentioned TP53-induced association between let-7 and AGO2 is functional.  
 
PAR-CLIP-seq identifies the mRNA targets of those miRNAs modulated by DSBs  
To identify the mRNA targets of those miRNAs modulated by DSBs, we treated HCT116 
TP53+/+ and TP53-/- cells with DOX and performed an AGO2 PAR-CLIP-seq experiment. 
After UV cross-linking, partial RNase digestion and AGO2 IP we prepared small RNA 
libraries from 9 replicates per treatment. We used the PARalyzer tool (Corcoran et al. 2011) 
to identify genome-wide AGO2 interaction sites from our PAR-CLIP data based on rate of T 
to C conversions and read density and obtained a total of 111,841 clusters of reads, 
representing AGO2 binding sites from all of the sequenced libraries (corresponding to a 
unique set of 54,256 sites). We then annotated the collection of AGO2 binding sites obtained 
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to genomic regions to evaluate AGO2 binding distribution and observed a neat binding 
preference for 3 prime untranslated regions (3'UTRs) and coding DNA sequences (CDSs) 
(Supplemental Fig. S8A). In fact it is known that miRNAs enact post-transcriptional 
repression of targets through interacting with coding CDSs (Tay et al. 2008) as well as 
3'UTRs and 5'UTRs (Lytle et al. 2007). Since clusters of reads derived from PAR-CLIP are 
selected by identifying T to C conversion sites (see Materials and Methods), they 
disproportionately arise from T-rich regions. This indicates that the AGO2 distribution in the 
various parts of the genes needs to be adjusted for T frequency in PAR-CLIP analysis. To this 
end we calculated the nucleotide frequency from 5'UTR, CDS and 3'UTR sequence 
annotations used here to map the PAR-CLIP sequencing reads (Supplemental Fig. S8B). As 
expected, Ts were more enriched in the 3'UTRs than the CDSs (T frequency equal to 29.68% 
and 21.78% respectively) (Supplemental Fig. S8B) and we used their frequencies to 
normalise PAR-CLIP cluster distribution (Supplemental Fig. S8C). After normalizing for T 
content, we found that AGO2 was almost equally distributed between 3'UTR and CDS 
regions (Supplemental Fig. S8C). 
Subsequently, we analysed occurrences of short sites matching the reverse-complement of 
miRNA canonical seed regions (Lewis et al. 2005), along with their evolutionary 
conservation, to assign AGO2 binding sites identified by the PAR-CLIP analysis to miRNAs. 
In accordance with previous findings (Hafner et al. 2010), the positional distribution of the 
first miRNA recognition element (MRE) nucleotide in each AGO2 binding site showed a 
preference for positions from -2 to +5 with respect to the predominant T to C transition within 
the clusters (Supplemental Fig. S9), and we used this information together with MRE 
conservation and length to prioritize the assignment of a single expressed miRNA to each 
AGO2 binding site where there was ambiguity due to multiple possible MREs (see Materials 
and Methods for further details). Since miRNAs also target genes in a “non-canonical” 
manner, through bulges and G:U pairs in the seed region (Chi et al. 2012; Helwak et al. 2013; 
Clark et al. 2014), and given our novel findings of an increased association between let-7 and 
AGO2 following DNA damage, we wished to complement our analysis by taking into 
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account potential non-canonical interactions between let-7 and their gene targets on AGO2. 
To achieve this we used the miRNA-mRNA interaction data from Clark and co-workers, 
available at https://cm.jefferson.edu/clip_2014/, that contains HITS-CLIP results from 
multiple cell lines (Clark et al. 2014), focusing on let-7 interactions and selecting those that 
overlapped with our AGO2 binding sites (Supplemental Table S5). Finally, based on the 
analysis of AGO2 binding sites and their assignment to targeting miRNAs, we built a 
comprehensive miRNA-mRNA interaction network (Supplemental Fig. S10). Noticeably, this 
miRNA-targetome network showed co-regulation of genes important for cell cycle 
progression including CCND1 and POGZ that were targeted by multiple up-regulated 
miRNAs and by let-7 members (Supplemental Fig. S10 and Supplemental Table S5). We 
validated by luciferase reporter assays the regulatory interaction of four different miRNAs 
(namely let-7a, let-7d, miR-23a and miR-34) that appeared to putatively co-regulate both 
CCND1 and POGZ (Supplemental Fig. S11). Among these the only experimentally validated 
interaction absent in the PAR-CLIP interaction network was the one between miR-34a and 
POGZ. Nevertheless we also included this potential interaction in the reporter analysis 
because of the relevance of miR-34a for the DNA damage response (He et al. 2007) and 
because an 8-mer matching to the miR-34a seed in POGZ 3′UTR is conserved among 
vertebrates (Supplemental Fig. S11). 
We then extracted the miRNA-mRNA pairs specific for the activated (either more abundant 
or more associated with AGO2) and repressed (either less abundant or less associated with 
AGO2) miRNAs in response to DSBs to evaluate the miRNA-mRNA interaction sub-
networks regulated by DSBs (Supplemental Fig. S10 -bottom left and -top right sub-
networks). Since coordinated transcription and miRNA-mediated post-transcriptional 
repression enhances robustness of gene regulation in mammals (Tsang et al. 2007), we 
wanted to evaluate the global overall impact of miRNA regulation on gene expression in 
response to DSBs. To this end we highlighted with green (down-regulation) or red (up-
regulation) coloring the gene expression changes elucidated by RNA-seq for genes involved 
in the networks of miRNA-mRNA interactions derived from the PAR-CLIP data analysis 
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(Supplemental Fig. S10). We used this approach to evaluate how these miRNAs coordinately 
affect genes that are up- or down-regulated following DSBs by other mechanisms, such as 
transcription. It appeared that miRNAs activated by DSBs targeted genes that were both up-
regulated and down-regulated by the DNA damage itself (Supplemental Fig. S10, 
Supplemental Fig. S12 and Supplemental Table S5), indicating that after their activation these 
miRNAs modulate the damage response through an intricate network of regulatory feedback 
and feedforward loops, supporting published models of miRNA regulation (O'Donnell et al. 
2005; Tsang et al. 2007; Castellano et al. 2009). Interestingly, the sub-network relative to 
targets of the let-7 family members (Supplemental Fig. S10 bottom-right and Supplemental 
Table S5) was enriched for cell cycle and TP53-signaling pathways (Fig. 5A). This indicates 
that the TP53-dependent increase in binding of let-7 family members with AGO2 actively 
participates in the DSBs response.  
 
let-7-mRNA chimeric reads from PAR-CLIP-seq are significantly more abundant after 
DOX treatment in TP53 wild type cells compared with untreated cells 
We then implemented a computational pipeline to identify unequivocal interactions between 
miRNAs and their targets by analysing the miRNA-mRNA fusion products (chimeras) 
originating from endogenous ligase activity during the PAR-CLIP procedure (Grosswendt et 
al. 2014) (Fig. 5B, Supplemental Fig. S13 and Supplemental Table S6). Analysis of the 
distribution of the last nucleotide in both the miRNA and the target region of the selected 
chimera candidates confirmed a high prevalence of G (Supplemental Fig. S14A), as 
previously shown (Grosswendt et al. 2014). In addition, the target region of the identified 
chimeras substantially map to 3'UTR regions in contrast to the PAR-CLIP data which showed 
a similar frequency of miRNA interactions in 3'UTRs and CDSs (Supplemental Fig. S8C and 
Supplemental Fig. S14B). This indicates that miRNA-mRNA chimeras could be 
preferentially formed from 3'UTR regions. We were unable to identify interactions for many 
abundant miRNAs suggesting that the ligation between miRNAs and targets occurs more 
frequently for some miRNAs than others. We also observed that the sequences corresponding 
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to the target regions obtained from the chimeras harbour a seed match for the cognate miRNA 
far more frequently than found in a set of random sequences (Supplemental Fig. S14C).  
As expected, when we extended the sequences of the target part of the chimeras (to look for 
seed matches, as RNase digestion often shortens their length), we found that 5-mer matches 
complementary to the miRNA seed region occurred much more frequently than when adding 
random nucleotides (Supplemental Figure S14C). Notably, 5-mer matches were more 
frequent than both 6- and 7-mers combined (Supplemental Figure S14C), suggesting that 5-
mers alone in the seed may be of great relevance for miRNA-target interaction.  
Separately, and also as expected, 4-mer windows of complementarity to the target were most 
often enriched from the second position of 5’ end of the miRNA (Supplemental Figure S15) 
again supporting the chimeras as bona fide target-miRNA hybrids. 
 
Motif enrichment analysis of the chimera target sites indicated that those recognized by let-7 
members tend to have more consistent perfect base-pairing to positions 3, 4 and 7 of the 
miRNA-seed region compared to other nucleotides in the seed, which show higher mismatch 
frequency (Fig. 5C and Supplemental Fig S14 A, B), although different members of the let-7 
family appear to have a slightly different recognition modes (Fig. 5D and Supplemental Fig 
S16 A, B). Interestingly, by plotting the positional distribution of the best match for each 
motif identified as enriched in let-7c and let-7b target sequences, we found that the motif 
corresponding to the seed region was centred, with a peak between the centre (0) and the -10 
position of the analysed dataset of target sequences (Supplementary Figure S16C, D). 
Notably, only let-7c targets were associated with U rich motifs peaking next to the miRNA-
mRNA ‘seed’ interaction sites (Supplementary Figure 13C, position between -30 and -20 of 
the graph), indicating that an additional RNA binding protein(s) might contribute to let-7c-
mRNA target regulation. Importantly, the percentage of formed let-7c-5p-target chimeric 
reads significantly increased with DOX treatment (Fig. 5D), once again confirming that the 
TP53-dependent increase in interaction between let-7 family members and AGO2 
functionally influences the DNA damage regulated miRNA-targetome.  
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Discussion 
In this study we identified an unprecedented role for TP53 in interacting with AGO2 and 
modulating the association between a subset of miRNAs and AGO2 during the DNA damage 
response. Although a recent study demonstrated that hypoxia suppressed AGO2-mediated 
maturation of a group of miRNAs (Shen et al. 2013), to the best of our knowledge our data 
represents the first evidence that an external stimulus could impact the association between 
specific miRNAs and AGO2, and that this mechanism is unrelated to variations in their 
abundance. This indicates that an AGO2-miRNA interaction but not regulation of miRNA 
biogenesis is responsible. In particular, we found that the expression levels of specific let-7 
family members, which usually act as tumor suppressor miRNAs negatively regulating cell 
cycle and differentiation processes (Boyerinas et al. 2010), are not differentially expressed 
following DSBs caused by DOX treatment. Rather, we observed modulation of the 
association of these and other miRNAs with the RISC complex. Moreover, we used state-of-
the-art whole-genome techniques (including RIP-seq and PAR-CLIP-seq) and computational 
methods [such as the determination of miRNA-mRNA chimeras formed by endogenous 
ligase activity during the PAR-CLIP procedure (Grosswendt et al. 2014)] to evaluate the 
targeting networks of the DOX regulated miRNAs. Using these techniques, we found that 
mRNAs that were more bound onto AGO2 following DOX treatment (indicative of miRNA 
post-transcriptional regulation mediated by the DNA damage response) were enriched for let-
7 seed matches. We should mention that due to the selection of T-to-C conversions during 
PAR-CLIP analysis, sites lacking Us in the clusters of reads could have been missed.  
 
Importantly, the let-7-mRNA chimeras that formed upon DOX treatment were significantly 
more abundant in DOX-treated samples in TP53+/+ but not TP53-/- cells. These results indicate 
that a TP53-mediated increase of let-7 miRNAs association with AGO2 following DOX 
treatment functionally influences the repression of their targets. Consistent with this finding, 
the let-7-regulated gene signature that we discovered showed functional enrichment in cell 
cycle and TP53-signaling pathways. Notably we found that mismatches in the seed of let-7 
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members did not occur randomly, but were seen with much greater frequency at specific 
positions. Our finding that 5-mer seed matches represent a higher proportion of the miRNA-
targetome than 6-mer and 7-mer matches combined, indicates that this mode of miRNA 
binding could be sufficient for miRNA regulation, more often than is currently appreciated.  
Furthermore, we showed that various oncogenic mutant forms of TP53 decreased miRNA 
binding onto AGO2 rather than increasing it, as observed for wild-type TP53. This suggests 
an additional oncogenic mechanism through which these mutant TP53 variants function, that 
implies loss of their capability to mediate let-7 association with AGO2 following DNA 
damage. Although the mechanism by which TP53 might regulate the association of certain 
miRNAs with AGO2 remains unknown, it is possible to speculate that TP53 interacting with 
AGO2 may modify the conformation of AGO2 or other RISC components and consequently 
change their affinity for a subset of miRNAs. Furthermore, the variable effect on miRNA-
AGO2 associations that we observed using TP53 mutants suggests that TP53’s regulation of 
AGO2 binding may be dependent of its conformation, since these missense mutants can have 
local (R248W and R273H) or more comprehensive (R175H) conformational changes (Sigal 
and Rotter 2000). In conclusion, this report reveals a novel role for TP53 in regulating the 
DNA damage response, demonstrating an additional mechanism of miRNA regulation with 
relevance to cancer progression.  
 
Methods 
Plasmid transfection, RT-qPCR, 3'UTR luciferase reporter assay, bioinformatic processing of 
the RNA-seq data and the statistical approaches as well as additional details are provided in 
the Supplemental Methods. 
 
Cell culture and DOX treatment. 
HCT116 TP53+/+ and TP35-/-, DLD1 and RKO cell lines were maintained in Dulbecco's 
modifed Eagle's medium or McCoy's medium supplemented with 10% FCS, 1% 
penicillin/streptomycin and 2% glutamine. Cells were plated in 150mm dishes at a 50% 
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confluence and incubated at 37 °C in a humidified 5% CO2 incubator. They were then treated 
with DOX at a concentration of 0.2ug/ml or equivalent volume of vehicle (ddH20). After 
each treatment time point, dishes were placed on ice and medium was aspirated. Cells were 
washed twice with cold PBS, scraped and centrifuged for 5 minutes at 1300 rpm. The 
supernatant was removed and the cell pellet was processed for RNA using TRIzol reagent 
(Invitrogen) and/or protein extraction. 
 
Preparation of the RNA and small RNA libraries.  
RNA and small RNA libraries were produced using the Illumina TruSeq RNA Sample Prep 
Kit and Small RNA Sample Prep Kit respectively (Illumina), as per the manufacturer's 
protocols. For both procedures, 200ng of RNA were used from the immunoprecipitation 
samples and 4ug from the input samples. For the RNA sequencing (RNA-seq), paired-end 
sequences (reads) of 100nt in length were then generated using a HiSeq 2000 instrument 
(Illumina). For the small RNA-seq, single-end reads of 50nt in length were generated using a 
HiSeq 2000 instrument (Illumina).  
 
AGO2 RNA Immunoprecipitation (RIP).  
Cells were plated and treated with DOX at a concentration of 0.2ug/ml or equivalent volume 
of vehicle for 24 hours. Cells were washed in cold PBS, scraped and then lysed with a buffer 
containing 0.5% Nonidet, 0.5mM DTT, 20mM Tris-HCL pH7.5, 150mM KCL, 2mM EDTA, 
1mM NaF and inhibitors of 1 RNases, proteases and phosphatases. 10% of total lysate was 
removed and kept as the input samples and the remainder used for immunoprecipitation. 10ug 
of anti-AGO2 (11A9, SAB4200085, Sigma-Aldrich) or anti-IgG (Sigma-Aldrich) antibodies 
were bound to sepharose beads in the presence of heparin. Pre-cleared lysates were then 
incubated with the appropriate antibody-bound beads and the immunoprecipitated proteins 
were then washed and incubated with DNase I in the presence of DNAse buffer (Promega) 
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followed by protease K (New England Biolabs) in the presence of 2x protease buffer (New 
England Biolabs). RNA extraction was then performed using phenol-chloroform separation 
and ethanol/sodium acetate precipitation. RNA pellets were washed in ethanol and quantified 
using a Nanodrop.  
 
AGO2 PAR-CLIP.  
PAR-CLIP was performed as previously described (Hafner et al., 2010), with minor 
modifications. Briefly, a total of 400 million cells were used for each experiment. Each plate 
was treated with 4-Thiouridine (Sigma-Aldrich) at a final concentration of 100uM, 14 hours 
prior to UV-crosslinking with 0.15J/cm2 of 365nm UV light with a Stratalinker UV 
Crosslinker (Stratagene). Cells were then scraped, lysed and digested with RNase T1 
(Fermentas) to a final concentration of 1U/µl. AGO immunoprecipitation of the lysate was 
then performed using Dynabeads Protein G magnetic particles (Invitrogen) and AGO 
antibody (Sigma) at a final concentration of 0.05ug/µl. A second RNase T1 treatment was 
then performed using a final concentration of 10U/µl. The RNA segments were then 
radiolabelled using 32P-γATP to a final concentration of 0.5uCi/µl and T4 PNK to a final 
concentration of 1U/µl and samples were then resuspended in 70µl of SDS-PAGE loading 
buffer and SDS-PAGE was performed. The gel bands corresponding to AGO were cut for 
each sample and electroelution of the crosslinked RNA- protein complexes was then 
performed. Recovery of cross-linked target RNA fragments was then performed using 
phenol-chloroform and ethanol extraction.  
 
Co-IP and RNase treatment. 
Cells were plated and treated with DOX at a concentration of 0.2ug/ml or equivalent volume 
of vehicle for 24 hours unless stated. After washing with cold PBS, cells were scraped 
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following lysing with RIPA buffer. 10% of total lysate was removed and kept as the input 
samples and the remainder was used for immunoprecipitation following ImmunoCruz Optima 
Immunoprecipitation protocol, provided with Optima B and C (Santa Cruz Biotechnology). 
Pre-clearing Matrix B and C were used for optimal pre-clearing of the lysate (Santa Cruz 
Biotechnology). The following antibodies were used during the immunoprecipitation and 
immunoblotting: anti-TP53 (DO-1, sc-126; Santa Cruz), anti-AGO2 (ab32381, Abcam), anti-
DDX5 (ab21696, Abcam), IgG (Santa Cruz). 
To check for RNA-dependence in TP53-AGO2 interaction, matrix-bound complexes were 
incubated with RNase A (Sigma) for 30 minutes at 37°C. Following incubation, samples were 
spun down and separated into supernatant- and bead-containing fractions and subjected to 
immunoblot analysis. 
 
Immunofluorescence  
Following treatment with DOX, cells were fixed with 4% paraformaldehyde in PBS for 10 
min, excess of which was subsequently quenched with 0.5 M glycine in PBS for 20 min at 
RT. For cell permeabilization, 0.3% Triton X-100 was added for 10 min. Next, cells were 
incubated with blocking buffer (5% goat serum, 1% BSA, 2% FCS in PBS) for 30 min 
followed by incubation with mouse monoclonal anti-TP53 antibody (1:100; sc-126, Santa 
Cruz) and rabbit polyclonal anti-Ago2 (1:250; ab32381, Abcam) for 1 h at RT. Cells were 
washed three times with 1% BSA and 2% FCS in PBS and incubated with Alexa 488 (anti-
rabbit; Invitrogen) and 568 (anti-mouse; Invitrogen) for 2 h at RT. Next, cells were washed 
twice with 1% BSA and 2% FCS in PBS and incubated with 4% paraformaldehyde for 10 
min at RT. Samples were subsequently washed twice with PBS and mounted using 
Mowiol® 4-88 (Calbiochem) with DAPI. Slides were analysed using a Leica TCS SP5 
confocal laser-scanning microscope and analysed using ImageJ software.  
 
Duolink® proximity ligation assay (PLA®). 
 Cold Spring Harbor Laboratory Press on January 31, 2016 - Published by genome.cshlp.orgDownloaded from 
TP53 regulates miRNA-AGO2 association 
 
 
19 
 
After treatment with DOX, fixation, permeabilization, blocking and primary antibody 
incubation steps were performed as described in the immunofluorescence section. Once cells 
were washed three times with 1% BSA and 2% FCS in PBS, incubation with PLA probes 
(i.e., anti-rabbit PLUS, anti-mouse MINUS PLA probes), ligation, amplification and 
mounting of the coverslips were all performed per manufacturer's instruction (Sigma-
Aldrich). Slides were imaged using a Leica TCS SP5 confocal laser-scanning microscope and 
analysed using ImageJ software. The number of PLA foci was manually counted in a blind 
fashion (100 cells per each condition in the three independent experiments). Cyto-3 plasmic 
foci were defined as fuorescent spots that did not co-localise with the nuclei stained with 
DAPI. Statistical significance in the number of PLA foci was tested by using a two-tailed t-
test. 
 
Data access 
Sequencing data have been deposited in the European Nucleotide Archive (ENA; 
http://www.ebi.ac.uk/ena) where they are accessible through the following study identifiers: 
PRJEB3157 and PRJEB3233, for small and long RNAs sequencing data, and PRJEB3396, for 
PAR-CLIP data. 
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Figure legends.  
Figure 1. TP53 is required for DNA damage-induced modulation of the association 
between AGO2 and a subset of miRNAs. 
(A), Barplot of fold changes for 53 miRNAs exhibiting statistically significant (Benjamini-
Hochberg adjusted Student's t-test P-value < 0.05) differential expression of small RNAs 
isolated from immunoprecipitated AGO2 after DOX treatment. In some cases (12/53 
miRNAs marked by an "&" symbol in the barplot x-axis labels), the observed changes in 
levels of AGO2 binding reflect changes in abundance in total RNA induced by the 
treatment. In other cases (41/53 miRNAs marked by an "o" symbol in the barplot x-axis 
labels), however, the observed changes in AGO2 binding occur in the absence of changes in 
abundance in total RNA. (B) Scatterplot showing miRNAs that change significantly in both 
the AGO2-immunoprecipitation and total RNA samples (HCT116 TP53+/+ cells). (C) 
Scatterplot showing miRNAs that significantly change in the AGO2-immunoprecipitation but 
not in the total RNA samples (HCT116 TP53+/+ cells). (D) Barplot of fold changes for 9 
miRNAs exhibiting statistically significant (Benjamini-Hochberg adjusted Student's t-test P-
value < 0.05), and TP53-independent, changes in expression. For these miRNAs, changes in 
AGO2 binding reflect changes in abundance in total RNA (9/9 miRNAs marked by an "&" 
symbol in the barplot x-axis labels). In panels (A) and (D), each bar represents the mean and 
standard deviation of three biological replicates. In panels (B) and (C), thicker dotted grey 
lines indicate the selected log fold change cut-off (0.35) and thinner dotted grey lines indicate 
a log fold change equal to 0.  
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Figure 2. DOX-induced DNA damage induces TP53-dependent differential binding of 
specific miRNAs to AGO2. (A), Fold changes in let-7 family levels determined by a 
combined small RNA-seq and AGO2-RIP-seq approach (miRNAs demonstrating a positive 
or negative fold change equal to or greater than the selected cut-off of 0.35 (log2) and a t-test 
P-value < 0.05 after correcting for multiple testing with the Benjamini-Hochberg method, 
were considered to be significant). (B & C), RT-qPCR analysis demonstrates that the binding 
of let-7 family members onto AGO2 is increased significantly in HCT116 TP53+/+ but not in 
TP53-/- cells following DOX treatment. (D), Time-course showing miR-34a and let-7 family 
fold changes following DOX-induced DNA damage in total RNA extracted from HCT116 
TP53+/+ cells. (E), Fold change in miR-148-5p expression in total RNA or AGO2-bound RNA 
samples following an AGO2 IP in DOX- or vehicle-treated HCT116 TP53+/+ and TP53-/- cell 
lines. (F), Fold change in let-7 and miR-34a expression following an AGO2 IP in DLD1 and 
RKO cell lines following DOX-induced DNA damage. (G), Fold change in let-7 family and 
miR-34a expression following an AGO2 IP in HCT116 TP53-/- cells transfected with 
plasmids expressing wild type or mutant TP53 (R175H, R248W, R273H).  
Abbreviations:  
IN: RNA isolated from input samples;  
IP: RNA isolated from the immunoprecipitated AGO2;  
Null: HCT116 TP53-/- cells;  
WT: HCT116 TP53-/- cells transfected with the plasmid expressing wild type TP53;  
R175H: HCT116 TP53-/- cells transfected with the plasmid expressing R175H TP53 mutant; 
R248W: HCT116 TP53-/- cells transfected with the plasmid expressing R248W TP53 mutant; 
R273H: HCT116 TP53-/- cells transfected with the plasmid expressing R273H TP53 mutant.  
At least three independent experiments have been performed in all cases 
 
Figure 3: AGO2 interacts with TP53 in an RNA-dependent manner. 
 Cold Spring Harbor Laboratory Press on January 31, 2016 - Published by genome.cshlp.orgDownloaded from 
TP53 regulates miRNA-AGO2 association 
 
 
22 
 
HCT116 TP53+/+ were treated with vehicle or DOX for 12h and co-immunoprecipitation 
assays were then performed to determine whether an interaction exists between TP53 and 
AGO2 proteins. (A), Reciprocal Co-IP experiments using AGO2 and TP53 antibodies 
demonstrate an interaction between the two proteins. DDX5 was used here as a positive 
control for the immunoprecipitation and ACTB was used as a loading control housekeeping 
gene in the input sample. (B), To test the impact of mutations in TP53 on its ability to interact 
with AGO2, TP53-/- cells were transfected with empty plasmid (null) or plasmids expressing 
mutated forms of TP53 (R175H, R248W and R273H), treated with DOX for 12 hours and 
subjected to Co-IP. (C), To investigate whether the association between the TP53 and AGO2 
is RNA-dependent, immunoprecipitates of AGO2 and TP53 from cells treated with DOX for 
12h were digested with increasing quantity of RNase A for 30 min at 37°C, separated into 
supernatant and beads and analysed by immunoblotting. 
At least three independent experiments have been performed in all cases.  
 
Figure 4: DNA damage increases the interaction between TP53 and AGO2 both in the 
cytoplasm and in the nucleus. 
(A), TP53-AGO2 PLA in HCT116 TP53+/+ cells shows that TP53 interacts with AGO2 after 
24 h of DOX treatment and this interaction also occurs in the cytoplasm, but is predominantly 
observed in the nucleus. (B), Absence of green spots over background level in TP53-/- 
HCT116 cells indicates that the interaction shown by the PLA in wild type cells, after 24h of 
DOX treatment (A) is specific. (C), Barplot showing quantification of PLA spots in the 
cytoplasm and in the whole HCT116 wild type cells. Slides were imaged using a Leica TCS 
SP5 confocal laser-scanning microscope and analysed using ImageJ software. The number of 
PLA foci was manually counted in a blind fashion (100 cells per each condition in each of 
three independent experiments). Cytoplasmic foci were defined as fluorescent spots that did 
not co-localise with the nuclei stained with DAPI. (Two tailed Student’s t-test).  
At least three independent experiments have been performed in all cases.  
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Figure 5: let-7-mRNA chimeras are significantly more abundant after DOX treatment 
in TP53 wild type cells compared with untreated cells 
 (A), KEGG pathways enrichment analysis performed using clusterProfiler 
(https://www.bioconductor.org/packages/3.3/bioc/html/clusterProfiler.html) for the list of 
genes included in the let-7 subnetwork. (B), Circos (http://circos.ca/) (Krzywinski et al. 2009) 
circularly layered heatmaps and histograms from different experiment data tracks produced in 
the present study mapped on the human genome (hg19). From outer to inner circle: heatmap 
of gene expression changes obtained from RNA-seq and AGO2-RIP-seq data performed in 
DOX-treated versus vehicle-treated samples in HCT116 TP53+/+ and TP53-/- cells; as 
previously stated, but for miRNAs; histograms of changes in PAR-CLIP cluster abundance in 
DOX-treated versus vehicle-treated samples for HCT116 TP53+/+ and TP53-/- cells. Heatmaps 
and histograms in the figure render values of observed log-fold changes on a green (lower 
values) to red (higher values) scale. Ribbons in the circle center show miRNA-target 
interactions identified by analysis of chimera reads (i.e. ligation products including part of the 
mature miRNA and part of its binding site sequence) from the PAR-CLIP experiment. (C), 
Result of motif analysis performed by using MEME (http://meme.nbcr.net/meme/) (Bailey et 
al. 2015) on the chimera target sites identified for let-7c. (D), Barplots of the percentage of 
total chimera reads in DOX-treated samples compared to vehicle-treated samples. 
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